Craig Parker: Yes. We’ll publish some of the pharmacokinetic data at some point for both molecules, but 043 was roughly in line with our PK projections from animals. We’re — Dae Gon, we’re not going to disclose all the dosing cohorts, but it’s a pretty typical dose level strategy. And we can continue to go above 1. And it’s possible, for example, that we could go up to 2.5, where we’ve seen one of these events with a different route of administration. So one potential hypothesis, for example, is that Cmax may be a contributor. We don’t have preclinical data suggesting that, but it’s seen with other molecules, and we’re giving the molecule IV. And we may ultimately want to test whether there’s a difference at doses we’ve tested IV with the subcutaneous dose. So…
Operator: Our next question comes from Hannah Adeoye with JPMorgan.
Hannah Adeoye: It’s Hannah on for Eric. Just a few from us. Have you commented on the half-life of 1326 before? And if so, are you able to speak to any of the expected dosing regimens or frequency for a multiple ascending dose study based on your preclinical and clinical findings thus far? I guess, generally, I’m trying to see what gives you comfort that the AEs you’ve observed initially…
Craig Parker: Hannah, I couldn’t hear that, I don’t know if others could.
Hannah Adeoye: Okay. I can repeat. I was saying, have you guys commented on the half-life of 1326? And are you able to speak to any expected dosing regimens or frequencies for a multiple ascending dose study based on your preclinical and clinical findings thus far? Just trying to see if there’s any data points to give you comfort that the AEs that you’ve observed thus far won’t be seen over longer dosing intervals? Were you able to get that?
Operator: One moment, please, the conference will begin momentarily. Go ahead, Hannah.
Hannah Adeoye: Can you guys hear me now?
Craig Parker: Yes.
Hannah Adeoye: Just was asking about the half-life of 1326 and your expected dosing regimen or frequencies for a multiple ascending dose study.
Craig Parker: The half-life is about — for 1326, you’re asking, correct?
Hannah Adeoye: Yes.
Craig Parker: The half-life is about 5 days. Keep in mind, though, that because there are a number of Wnt pathway target genes that are activated when you activate the pathway, the biological effects could be longer lasting than the — what you might anticipate from the half-life of the antibody. And so it’s not a straightforward align the PK with the frequency of dosing. So we think this could be in every other week or perhaps even less frequent dosing regimen. We have not finalized that yet for the Phase Ib portion. And obviously, we want to see all the human PK data at different dose levels. That half life, by the way, was in primates for 5 days.
Operator: . Our next question comes from Yatin Suneja with Guggenheim.
Yatin Suneja: Can you guys hear me?
Operator: Yes, you’re coming in loud and clear.
Craig Parker: I can’t hear him.
Yatin Suneja: Craig, can you hear me now? Once I get signal from the company I’ll ask the question.
Operator: Craig, please give us the word when you can hear us?
Craig Parker: I can hear you. I can’t hear Yatin.
Yatin Suneja: Now? Hello? I think we are able to hear. I don’t know because the other line is able to hear. Chuck, can you hear us?
Charles Williams: I can hear you. Craig, can you hear Yatin?
Craig Parker: No.
Charles Williams: You can hear me?
Craig Parker: Yes. Can you translate the question?
Charles Williams: Why don’t we do that.
